SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron)

SARS-CoV-2 Omicron variant, a variant of concern (VOC), known as B.1.1.529, was detected in South Africa at the end of November in 2021. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 90% of the new cases. Omicron variant spike protein carries around 30 amino acid changes, including mutations, deletions and insertions, 15 of which are in the receptor binding domain (RBD) . Enhanced transmission of the Omicron variant was observed globally, which is at least 70 times more contagious than the other variants. The Omicron variant affects the effectiveness of COVID-19 vaccine and is resistant to neutralization (monoclonal antibody treatments) to a large extent.

43740568

P0DTC2

QHD43416

Peptides

200 ug/mL

PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide

Blue Ice

Store SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron) at -20˚ C, stable for one year.

SARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Peptide (Omicron) is used for blocking the activity of theSARS-CoV-2 (COVID-19) Spike G142D Δ143-145VYY Antibody (Omicron)

Surface glycoprotein

Severe acute respiratory syndrome coronavirus 2

Gowrisankar et al. European Physical Journal Plus, 2022, 137 (1), 100.

Zhang et al. PNAS of U.S.A. 2021, 118 (47) :e2109905118.

Cameroni et al. Nature 2021.

Rossler et al. NEJM 2022.

Muik et al. Science 2022.

SARS-CoV-2 Omicron Variant Spike antibody: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein, Omicron Variant

Blocking

SARS-CoV-2

1791269090

Liquid